Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
ML

NASDAQ · MLTX

MoonLake Immunotherapeutics

Healthcare · Biotechnology

$11.78

Down-$0.79 (-6.28%)

Updated Nov 1, 2026, 12:11 PM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
895.62M
P/E ratio
-5.04
Dividend yield
0.00%
52-week range
$9.46 – $23.29
Volume
1.13M
Avg. volume
5.18M

Price performance · MLTX

MLTX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

MLTX closed at $11.78 after 20 trading sessions, up 3.51% for the selected period.

Last close
$11.78
Period change
+3.51%
Period low
$9.55
Period high
$12.57
Daily close
View OHLC price history
MLTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$12.44$12.6296$11.71$11.781.13M
Oct 29, 2026$12.36$12.95$12.31$12.574.1M
Oct 28, 2026$11.87$12.38$11.71$12.311.21M
Oct 27, 2026$11.77$12.10$11.54$11.93934.42K
Oct 26, 2026$11.77$12.46$11.665$11.811.51M
Oct 23, 2026$12.07$12.28$11.48$11.851.94M
Oct 22, 2026$10.70$13.334$10.65$12.346.12M
Oct 21, 2026$10.34$10.73$10.34$10.651.16M
Oct 20, 2026$9.77$10.48$9.731$10.321.24M
Oct 19, 2026$9.57$9.8625$9.50$9.75911.74K
Oct 16, 2026$10.34$10.34$9.46$9.551.38M
Oct 15, 2026$10.16$10.505$10.1354$10.261.07M
Oct 14, 2026$10.30$10.65$10.005$10.141.77M
Oct 13, 2026$10.70$10.84$10.355$10.412.41M
Oct 12, 2026$10.82$11.00$10.66$10.681.21M
Oct 9, 2026$10.58$11.09$10.40$10.822.01M
Oct 8, 2026$10.75$10.795$10.00$10.583.72M
Oct 7, 2026$10.81$11.29$10.71$10.771.4M
Oct 6, 2026$11.50$11.50$10.91$10.953.05M
Oct 5, 2026$11.56$11.715$11.19$11.381.87M

Latest MLTX news

The latest Smart Investors Daily articles mentioning MLTX.

Stock researchCompany · Overview

MLTX research

Overview

Company profile and research snapshot.

Company profile

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$17.29
Implied upside
—
Analysts
24
MLTX recent ratings
DateFirmRatingTarget
Oct 5, 2026HC Wainwright & Co.Buy—
Aug 13, 2026HC Wainwright & Co.Buy—
Jul 20, 2026HC Wainwright & Co.Buy—
Jul 1, 2026Leerink PartnersOutperform—
Jun 9, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 25, 2026

MoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View Holds

Recent Performance Snapshot MoonLake Immunotherapeutics (MLTX) has drawn fresh attention after recent trading saw the share price close at $11.85. Performance has been mixed across timeframes and marked by sharp moves over the past 3 months. That recent jump in MoonLake Immunotherapeutics, with a 7-day share price return of 24.08%, comes after a much weaker 90-day share price move that declined 40.39%. Meanwhile, the 1-year total shareholder return of 24.47% contrasts sharply with a 3-year...

Yahoo · Oct 25, 2026

MoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet Questions

MoonLake Immunotherapeutics has seen sharp swings in its share price in recent years, which puts fresh focus on what investors are really paying for on the balance sheet. With the stock last closing at US$11.85, the live question is how that market tag lines up with the company’s book value. The share price has fallen 76.3% over the past 3 years. This long term slide raises a direct question about how much equity value MoonLake Immunotherapeutics is now being credited with. For a clinical...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By